There appeared to be no difference in DDX21 expression in the late stage colorectal cancer cohort, as positive DDX21 expression was detected in 30.3% (20/66) of stage III and 32.0% (8/25) of stage IV patients (Table 2). This evidence concerns the gene DDX21 and colorectal cancer.